Clinical Trial Finder

Inclusion Criteria:

1. Inclusion within 3 months after diagnosis. 2. Availability of a cryopreserved tumour sample (primary and/or metastatic and/or lymph nodes) or peripheral blood or bone marrow samples (if invasion more than 30% of lymphoblasts) for leukaemias, obtained at the time of diagnosis during a routine procedure. 3. Availability of a formalin-fixed paraffin-embedded (FFPE) tumour sample (primary and/or metastasis and/or lymph nodes), obtained at the time of diagnosis during a routine procedure (except for leukaemia patients) 4. Age: ≤ 25 years at diagnosis. 5. Written patient informed consent, or parents or legal representative written informed consent and assent of the child and the adolescent. 6. Compulsory affiliation to a social security scheme. Additional inclusion criteria for the study: To avoid multiple sampling for children, adolescents and young adults with cancer, patients already included or to be included in a study with similar analyses and/or objectives might also be included in MICCHADO study and in this case, samples or data might be exchanged on a collaborative basis. Cohort 1:

• - High risk neuroblastoma: - Any type of neuroblastoma with MYCN amplification, except INSS stage 1.

• - Stage 4 neuroblastoma in children older than one year at diagnosis.

• - High risk rhabdomyosarcoma: - Foxo1 rearrangement any stage; - and / or N1 ; - and / or metastatic rhabdomyosarcoma.

• - High risk Ewing sarcoma: - Metastatic Ewing sarcoma family of tumours (ESFT) - Localised inoperable Ewing sarcoma with primary tumours ≥ 200 ml.

• - High risk osteosarcoma: - Metastatic osteosarcoma.

• - Localised inoperable osteosarcoma.

• - High risk leukaemia: - Secondary acute myeloid leukaemia.

• - Biphenotypic acute leukaemia.

Cohort 2: • Extra cerebral or cerebral high risk tumours including:

• - other metastatic sarcomas, - other rare high risk cancers, - high risk renal tumours with surgery after an initial chemotherapy.

• - rhabdoid brain tumours (AT/RT) and extra cerebral rhabdoid tumours.

• - high risk or metastatic cancers of unclear histological diagnosis • Lymphoblastic leukaemia with high MRD at Day 78 (time point 2) • Very high risk T-cells acute lymphoblastic leukaemia: - MRD ≥ 10-2 at the end of the induction ; - or MRD ≥ 10-3 at Day 78.

Cohort 3: Children, adolescents and young adults, with low/intermediate risk cancers belonging to the following types: • Neuroblastoma:

• - Localised, without MYCN amplification.

• - Localised, INSS stage 1, with MYCN amplification.

• - Stage 4s, in infants (younger than one year at diagnosis), without MYCN amplification.

• Rhabdomyosarcoma:

• - Localised, without Foxo1 rearrangement.

• ESFT:

• - All non-high risk localised ESFT • Osteosarcoma: - All non-high risk localised osteosarcoma.

Exclusion Criteria:

Main non-inclusion Criteria common to all study cohorts: 1) Age: patients > 25 years old at diagnosis 2) Absence of patient or parents or legal representative written informed consent 3) Patient for whom follow-up by the investigating centre does not appear feasible

To identify and characterise:

• - meaningful molecular genetic alterations, - meaningful immunological features of high risk childhood, adolescents and young adult cancers, at diagnosis, during patient treatment and follow-up (time dimension).

Arms

Experimental: High risk Cohorts

Cohort 1 : High risk Neuroblastoma, High risk Rhabdomyosarcoma, High risk Ewing Sarcoma Family Tumor, High risk Osteosarcoma, High risk Leukaemia (secondary acute myeloid leukaemia or biphenotypic acute leukaemia) Cohort 2 : Extracerebral and cerebral high risk tumor, High risk Leukaemia (leukaemia with high MRD) Sampling on blood, bone marrow and cerebrospinal fluid

Experimental: Low risk Cohort

Cohort 3 : Intermediate or low risk tumors : Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family Tumor, Osteosarcoma Sampling on blood, bone marrow and cerebrospinal fluid

Interventions

Other: - Sampling on blood, bone marrow and cerebrospinal fluid

biological sampling during treatment and follow-up